Stammdaten
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Unternehmen & Branche
| Name | GALECTIN THERAPEUTICS INC |
|---|---|
| Ticker | GALT |
| CIK | 0001133416 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 363225129 |
|---|---|
| ISIN | US3632251290 |
| Typ | Common Stock |
| Marktkapitalisierung | 148,8 Mio. USD |
| Beta | 1,04 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -30,836,000 | -0.48 | 19,532,000 | -127,918,000 | |
| 2025-09-30 | 10-Q | -8,184,000 | -0.13 | 12,865,000 | -125,303,000 | |
| 2025-06-30 | 10-Q | -7,521,000 | -0.12 | 15,602,000 | -118,890,000 | |
| 2025-03-31 | 10-Q | -9,631,000 | -0.15 | 9,528,000 | -113,984,000 | |
| 2024-12-31 | 10-K | -47,047,000 | -0.76 | 17,495,000 | -104,793,000 | |
| 2024-09-30 | 10-Q | -11,220,000 | -0.18 | 28,972,000 | -94,204,000 | |
| 2024-06-30 | 10-Q | -12,371,000 | -0.20 | 27,655,000 | -83,870,000 | |
| 2024-03-31 | 10-Q | -11,489,000 | -0.19 | 25,890,000 | -44,369,000 | |
| 2023-12-31 | 10-K | -41,066,000 | -0.74 | 28,200,000 | -61,964,000 | |
| 2023-09-30 | 10-Q | -10,428,000 | -0.24 | 22,163,000 | -52,596,000 | |
| 2023-06-30 | 10-Q | -9,114,000 | -0.15 | 20,081,000 | -52,850,000 | |
| 2023-03-31 | 10-Q | -11,527,000 | -0.19 | 20,225,000 | -44,369,000 | |
| 2022-12-31 | 10-K | -38,776,000 | -0.65 | 21,285,000 | -33,917,000 | |
| 2022-09-30 | 10-Q | -8,597,000 | -0.14 | 17,914,000 | -24,058,000 | |
| 2022-06-30 | 10-Q | -9,613,000 | -0.16 | 25,886,000 | -16,946,000 | |
| 2022-03-31 | 10-Q | -9,932,000 | -0.17 | 33,615,000 | -7,916,000 | |
| 2021-12-31 | 10-K | -30,527,000 | -0.52 | 41,827,000 | 893,000 | |
| 2021-09-30 | 10-Q | -8,520,000 | -0.14 | 38,038,000 | 7,526,000 | |
| 2021-06-30 | 10-Q | -8,449,000 | -0.15 | 33,405,000 | 15,393,000 | |
| 2021-03-31 | 10-Q | -6,338,000 | -0.11 | 22,897,000 | 16,511,000 |
Fondsaktivität (Vorquartalsvergleich)
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | 2,288,848 | 0 | 2,288,848 | 9,521,608 | Neu | +100,0% | |
| OSAIC HOLDINGS, INC. | 1,090,590 | 0 | 1,090,590 | 4,536,850 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 881,619 | 0 | 881,619 | 3,667,535 | Neu | +100,0% | |
| BlackRock, Inc. | 796,558 | 0 | 796,558 | 3,313,681 | Neu | +100,0% | |
| GROUP ONE TRADING LLC | 649,100 | 0 | 649,100 | 2,700,256 | Neu | +100,0% | |
| MARSHALL WACE, LLP | 602,134 | 0 | 602,134 | 2,504,877 | Neu | +100,0% | |
| Wealthspire Advisors, LLC | 601,973 | 0 | 601,973 | 2,504,208 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 598,074 | 0 | 598,074 | 2,489,234 | Neu | +100,0% | |
| JANE STREET GROUP, LLC | 379,639 | 0 | 379,639 | 1,579,299 | Neu | +100,0% | |
| COMMONWEALTH EQUITY SERVICES, LLC | 334,096 | 0 | 334,096 | 1,389,840 | Neu | +100,0% | |
| LPL Financial LLC | 325,256 | 0 | 325,256 | 1,353,065 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 307,229 | 0 | 307,229 | 1,278,073 | Neu | +100,0% | |
| MORGAN STANLEY | 279,288 | 0 | 279,288 | 1,161,837 | Neu | +100,0% | |
| Geneos Wealth Management Inc. | 243,327 | 0 | 243,327 | 1,012,240 | Neu | +100,0% | |
| STATE STREET CORP | 242,232 | 0 | 242,232 | 1,007,685 | Neu | +100,0% | |
| MILLENNIUM MANAGEMENT LLC | 235,508 | 0 | 235,508 | 979,713 | Neu | +100,0% | |
| Vivaldi Capital Management LP | 204,070 | 0 | 204,070 | 848,931 | Neu | +100,0% | |
| RETIREMENT GUYS FORMULA LLC | 184,562 | 0 | 184,562 | 767,778 | Neu | +100,0% | |
| Sovran Advisors, LLC | 225,874 | 0 | 225,874 | 711,503 | Neu | +100,0% | |
| 683 Capital Management, LLC | 162,484 | 0 | 162,484 | 675,933 | Neu | +100,0% | |
| WELLINGTON MANAGEMENT GROUP LLP | 142,220 | 0 | 142,220 | 591,635 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 130,448 | 0 | 130,448 | 542,664 | Neu | +100,0% | |
| SIMPLEX TRADING, LLC | 125,979 | 0 | 125,979 | 524,072 | Neu | +100,0% | |
| BARCLAYS PLC | 106,401 | 0 | 106,401 | 442,628 | Neu | +100,0% | |
| Fortis Capital Advisors, LLC | 106,139 | 0 | 106,139 | 441,538 | Neu | +100,0% | |
| Belpointe Asset Management LLC | 106,139 | 0 | 106,139 | 441,538 | Neu | +100,0% | |
| ExodusPoint Capital Management, LP | 82,478 | 0 | 82,478 | 343,108 | Neu | +100,0% | |
| Hudson Bay Capital Management LP | 78,145 | 0 | 78,145 | 325,083 | Neu | +100,0% | |
| Qube Research & Technologies Ltd | 74,643 | 0 | 74,643 | 310,515 | Neu | +100,0% | |
| TRUIST FINANCIAL CORP | 68,000 | 0 | 68,000 | 282,880 | Neu | +100,0% | |
| XTX Topco Ltd | 51,936 | 0 | 51,936 | 216,054 | Neu | +100,0% | |
| HORIZON KINETICS ASSET MANAGEMENT LLC | 51,484 | 0 | 51,484 | 214,173 | Neu | +100,0% | |
| Pinnacle Financial Partners, Inc. | 48,000 | 0 | 48,000 | 199,680 | Neu | +100,0% | |
| UBS Group AG | 39,104 | 0 | 39,104 | 162,673 | Neu | +100,0% | |
| BLAIR WILLIAM & CO/IL | 37,884 | 0 | 37,884 | 157,597 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 29,985 | 0 | 29,985 | 124,738 | Neu | +100,0% | |
| CITADEL ADVISORS LLC | 27,500 | 0 | 27,500 | 114,400 | Neu | +100,0% | |
| Solutions 4 Wealth, Ltd | 25,377 | 0 | 25,377 | 105,568 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 25,063 | 0 | 25,063 | 104,262 | Neu | +100,0% | |
| Stratos Wealth Partners, LTD. | 19,088 | 0 | 19,088 | 79,406 | Neu | +100,0% | |
| MANGROVE PARTNERS IM, LLC | 18,783 | 0 | 18,783 | 78,137 | Neu | +100,0% | |
| TWO SIGMA INVESTMENTS, LP | 16,612 | 0 | 16,612 | 69,106 | Neu | +100,0% | |
| Squarepoint Ops LLC | 16,462 | 0 | 16,462 | 68,482 | Neu | +100,0% | |
| Jefferies Financial Group Inc. | 16,435 | 0 | 16,435 | 68,370 | Neu | +100,0% | |
| Cetera Investment Advisers | 14,220 | 0 | 14,220 | 59,155 | Neu | +100,0% | |
| RAYMOND JAMES FINANCIAL INC | 13,717 | 0 | 13,717 | 57,062 | Neu | +100,0% | |
| SIG BROKERAGE, LP | 13,596 | 0 | 13,596 | 56,559 | Neu | +100,0% | |
| BNP PARIBAS FINANCIAL MARKETS | 13,518 | 0 | 13,518 | 56,235 | Neu | +100,0% | |
| Argyle Capital Partners, LLC | 13,375 | 0 | 13,375 | 55,640 | Neu | +100,0% | |
| FMR LLC | 12,807 | 0 | 12,807 | 53,278 | Neu | +100,0% |
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-02-06 | ELDRED KARY | Director | Open Market Purchase | 300 | 2.70 | 810.00 | +1,2% | |
| 2026-01-06 | CALLICUTT JACK W | Officer, Chief Financial Officer | Open Market Sale | -20,354 | 3.67 | -74,695.11 | -111,1% | |
| 2026-01-06 | LEWIS JOEL | Director, Officer, President and CEO | Open Market Sale | -37,698 | 3.58 | -134,853.29 | -200,7% | |
| 2026-01-06 | Jamil Khurram | Officer, Chief Medical Officer | Open Market Sale | -21,446 | 3.65 | -78,204.98 | -116,4% | |
| 2026-01-05 | Jamil Khurram | Officer, Chief Medical Officer | Open Market Sale | -25,499 | 3.90 | -99,407.85 | -147,9% | |
| 2026-01-05 | LEWIS JOEL | Director, Officer, President and CEO | Open Market Sale | -27,731 | 3.91 | -108,342.24 | -161,2% | |
| 2026-01-05 | CALLICUTT JACK W | Officer, Chief Financial Officer | Open Market Sale | -25,732 | 3.90 | -100,298.19 | -149,2% | |
| 2026-01-02 | LEWIS JOEL | Director, Officer, President and CEO | Open Market Sale | -18,571 | 4.20 | -77,938.77 | -116,0% | |
| 2026-01-02 | Jamil Khurram | Officer, Chief Medical Officer | Open Market Sale | -13,055 | 4.20 | -54,789.22 | -81,5% | |
| 2026-01-02 | CALLICUTT JACK W | Officer, Chief Financial Officer | Open Market Sale | -13,914 | 4.20 | -58,394.28 | -86,9% | |
| 2025-12-31 | Jamil Khurram | Officer, Chief Medical Officer | Open Market Sale | -8,125 | 4.07 | -33,089.06 | -49,2% | |
| 2025-12-23 | FREEMAN KEVIN D | Director | Open Market Purchase | 5,500 | 3.55 | 19,514.00 | +29,0% | |
| 2025-12-23 | ELDRED KARY | Director | Open Market Purchase | 700 | 3.73 | 2,611.00 | +3,9% | |
| 2025-12-23 | FREEMAN KEVIN D | Director | Open Market Purchase | 5,500 | 3.55 | 19,514.00 | +29,0% | |
| 2025-12-23 | ELDRED KARY | Director | Open Market Purchase | 700 | 3.73 | 2,611.00 | +3,9% | |
| 2025-12-23 | FREEMAN KEVIN D | Director | Open Market Purchase | 5,500 | 3.55 | 19,514.00 | +29,0% | |
| 2025-12-17 | LEWIS JOEL | Director, Officer, President and CEO | Open Market Sale | -7,829 | 7.06 | -55,241.42 | -82,2% | |
| 2025-12-17 | Shlevin Harold H. | Director | Open Market Sale | -19,793 | 7.04 | -139,303.13 | -207,3% | |
| 2025-12-17 | Shlevin Harold H. | Director | Open Market Sale | -4,706 | 7.04 | -33,120.83 | -49,3% | |
| 2025-12-17 | Jamil Khurram | Officer, Chief Medical Officer | Open Market Sale | -8,500 | 7.04 | -59,840.00 | -89,0% | |
| 2025-12-17 | Jamil Khurram | Officer, Chief Medical Officer | Open Market Sale | -6,463 | 7.04 | -45,499.52 | -67,7% | |
| 2025-12-17 | Jamil Khurram | Officer, Chief Medical Officer | Open Market Sale | -4,479 | 7.04 | -31,532.16 | -46,9% | |
| 2025-12-15 | Shlevin Harold H. | Director | Open Market Sale | -8,417 | 6.30 | -53,027.10 | -78,9% | |
| 2025-12-12 | Shlevin Harold H. | Director | Open Market Sale | -19,793 | 6.27 | -124,181.28 | -184,8% | |
| 2025-12-09 | Shlevin Harold H. | Director | Open Market Sale | -16,790 | 6.27 | -105,206.14 | -156,5% | |
| 2025-12-08 | Shlevin Harold H. | Director | Open Market Sale | -20,000 | 5.96 | -119,240.00 | -177,4% | |
| 2025-12-08 | Shlevin Harold H. | Director | Open Market Sale | -4,000 | 6.01 | -24,020.00 | -35,7% | |
| 2025-12-08 | Shlevin Harold H. | Director | Open Market Sale | -20,000 | 5.96 | -119,240.00 | -177,4% | |
| 2025-12-08 | Shlevin Harold H. | Director | Open Market Sale | -20,000 | 6.00 | -120,040.00 | -178,6% | |
| 2025-12-08 | Shlevin Harold H. | Director | Open Market Sale | -25,000 | 5.95 | -148,650.00 | -221,2% | |
| 2025-12-08 | Shlevin Harold H. | Director | Open Market Sale | -35,000 | 5.95 | -208,250.00 | -309,9% | |
| 2025-12-08 | Shlevin Harold H. | Director | Open Market Sale | -35,000 | 6.02 | -210,665.00 | -313,5% | |
| 2025-11-18 | CALLICUTT JACK W | Officer, Chief Financial Officer | Open Market Sale | -18,210 | 6.22 | -113,320.83 | -168,6% | |
| 2025-11-18 | CALLICUTT JACK W | Officer, Chief Financial Officer | Open Market Sale | -28,100 | 6.22 | -174,866.30 | -260,2% | |
| 2025-11-18 | LEWIS JOEL | Director, Officer, President and CEO | Open Market Sale | -6,783 | 6.15 | -41,722.91 | -62,1% | |
| 2025-11-17 | CALLICUTT JACK W | Officer, Chief Financial Officer | Open Market Sale | -2,323 | 6.03 | -14,011.64 | -20,8% | |
| 2025-11-17 | CALLICUTT JACK W | Officer, Chief Financial Officer | Open Market Sale | -19,701 | 6.03 | -118,830.52 | -176,8% | |
| 2025-11-17 | LEWIS JOEL | Director, Officer, President and CEO | Open Market Sale | -15,680 | 6.04 | -94,642.91 | -140,8% | |
| 2025-11-17 | CALLICUTT JACK W | Officer, Chief Financial Officer | Open Market Sale | -9,586 | 6.03 | -57,819.88 | -86,0% | |
| 2025-11-13 | Jamil Khurram | Officer, Chief Medical Officer | Open Market Sale | -21,867 | 5.47 | -119,612.49 | -178,0% | |
| 2025-11-13 | Jamil Khurram | Officer, Chief Medical Officer | Open Market Sale | -41,500 | 5.47 | -227,005.00 | -337,8% | |
| 2025-11-13 | Jamil Khurram | Officer, Chief Medical Officer | Open Market Sale | -16,250 | 5.47 | -88,887.50 | -132,3% | |
| 2025-11-10 | CALLICUTT JACK W | Officer, Chief Financial Officer | Open Market Sale | -1,675 | 6.03 | -10,094.56 | -15,0% | |
| 2025-11-10 | CALLICUTT JACK W | Officer, Chief Financial Officer | Open Market Sale | -1,880 | 6.02 | -11,321.36 | -16,8% | |
| 2025-11-10 | CALLICUTT JACK W | Officer, Chief Financial Officer | Open Market Sale | -1,736 | 6.03 | -10,467.73 | -15,6% | |
| 2025-11-10 | LEWIS JOEL | Director, Officer, President and CEO | Open Market Sale | -1,867 | 6.03 | -11,252.22 | -16,7% | |
| 2025-11-05 | CALLICUTT JACK W | Officer, Chief Financial Officer | Open Market Sale | -200 | 6.00 | -1,200.00 | -1,8% | |
| 2025-11-05 | LEWIS JOEL | Director, Officer, President and CEO | Open Market Sale | -200 | 6.00 | -1,200.00 | -1,8% | |
| 2025-11-04 | CALLICUTT JACK W | Officer, Chief Financial Officer | Open Market Sale | -8,914 | 6.07 | -54,107.98 | -80,5% | |
| 2025-11-04 | CALLICUTT JACK W | Officer, Chief Financial Officer | Open Market Sale | -10,741 | 6.07 | -65,197.87 | -97,0% | |
| 2025-11-04 | CALLICUTT JACK W | Officer, Chief Financial Officer | Open Market Sale | -8,974 | 6.07 | -54,472.18 | -81,1% | |
| 2025-11-04 | LEWIS JOEL | Director, Officer, President and CEO | Open Market Sale | -14,420 | 6.07 | -87,529.40 | -130,2% | |
| 2025-11-03 | LEWIS JOEL | Director, Officer, President and CEO | Open Market Sale | -1,300 | 6.01 | -7,813.00 | -11,6% | |
| 2025-11-03 | CALLICUTT JACK W | Officer, Chief Financial Officer | Open Market Sale | -1,300 | 6.01 | -7,813.00 | -11,6% | |
| 2025-11-03 | CALLICUTT JACK W | Officer, Chief Financial Officer | Open Market Sale | -1,260 | 6.01 | -7,572.60 | -11,3% | |
| 2025-11-03 | CALLICUTT JACK W | Officer, Chief Financial Officer | Open Market Sale | -1,250 | 6.01 | -7,512.50 | -11,2% | |
| 2025-09-12 | LEWIS JOEL | Director, Officer, President and CEO | Open Market Sale | -14,000 | 6.36 | -89,048.40 | -132,5% | |
| 2025-09-12 | CALLICUTT JACK W | Officer, Chief Financial Officer | Open Market Sale | -8,706 | 6.44 | -56,053.58 | -83,4% | |
| 2025-07-21 | ELDRED KARY | Director | Open Market Purchase | 1,000 | 2.93 | 2,925.00 | +4,4% | |
| 2025-07-17 | FREEMAN KEVIN D | Director | Open Market Purchase | 5,000 | 2.90 | 14,495.00 | +21,6% |
Top-Fondshalter
Hinweis: Keine aktuelleren Daten zu dieser Aktie verfuegbar. Stand der gezeigten 13F-Holdings: 31.12.2025. Letztes global veroeffentlichtes 13F-Quartal: 31.03.2026.
| Fonds | Anteile | Wert (USD) | Anteil (%) |
|---|---|---|---|
| VANGUARD GROUP INC | 2,288,848 | 9,521,608 | 18.72 |
| OSAIC HOLDINGS, INC. | 1,090,590 | 4,536,850 | 8.92 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 881,619 | 3,667,535 | 7.21 |
| BlackRock, Inc. | 796,558 | 3,313,681 | 6.51 |
| GROUP ONE TRADING LLC | 649,100 | 2,700,256 | 5.31 |
| MARSHALL WACE, LLP | 602,134 | 2,504,877 | 4.92 |
| Wealthspire Advisors, LLC | 601,973 | 2,504,208 | 4.92 |
| GEODE CAPITAL MANAGEMENT, LLC | 598,074 | 2,489,234 | 4.89 |
| JANE STREET GROUP, LLC | 379,639 | 1,579,299 | 3.10 |
| COMMONWEALTH EQUITY SERVICES, LLC | 334,096 | 1,389,840 | 2.73 |
| LPL Financial LLC | 325,256 | 1,353,065 | 2.66 |
| GOLDMAN SACHS GROUP INC | 307,229 | 1,278,073 | 2.51 |
| MORGAN STANLEY | 279,288 | 1,161,837 | 2.28 |
| Geneos Wealth Management Inc. | 243,327 | 1,012,240 | 1.99 |
| STATE STREET CORP | 242,232 | 1,007,685 | 1.98 |
| MILLENNIUM MANAGEMENT LLC | 235,508 | 979,713 | 1.93 |
| Vivaldi Capital Management LP | 204,070 | 848,931 | 1.67 |
| RETIREMENT GUYS FORMULA LLC | 184,562 | 767,778 | 1.51 |
| Sovran Advisors, LLC | 225,874 | 711,503 | 1.40 |
| 683 Capital Management, LLC | 162,484 | 675,933 | 1.33 |